Shots: The EC approval is based on data from an ongoing P-II trial evaluating Libtayo in 119 patients with LA BCC or metastatic BCC (nodal or distant) previously treated with […]readmore
Tags : Basal Cell Carcinoma
Shots: The FDA approval is based on P-II trial involves assessing Libtayo (350mg, q3w) in patients with locally advanced BCC & metastatic BCC (nodal or distant) Results: median follow-up (9.5 […]readmore